Clinical trials: Disruptive Behavior Disorder Nos
ADHD
Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS
The primary objective of the study is to assess the efficacy and tolerability of a 12-week trial of memantine hydrochloride administered twice daily in 20 adults (ages 18-55) with ADHD and ADHD NOS.
- Trial name
- NCT00586573
- Testing
- memantine hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Pervasive Development Disorders
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
The purpose of this study is to determine whether guanfacine (trade name Intuniv) by itself or in combination with methylphenidate (also known as Ritalin) is helpful for treating hyperactivity in children and adolescents with a…
- Trial name
- NCT01238575
- Testing
- extended-release guanfacine
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Yale University
Mood Disorder, Mental Disorder Diagnosed in Childhood
A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
Severe mood dysregulation (SMD) is a very common syndrome in children. Its symptoms include very severe irritability, including persistent anger and frequent outbursts, as well as distractibility, hyperactivity, and other…
- Conditions
- Mood Disorder, Mental Disorder Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT00794040
- Testing
- Add-on citalopram following optimized methylphenidate
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Institute of Mental Health (NIMH)
Autism, Pervasive Development Disorder
Atomoxetine, Placebo and Parent Management Training in Autism
The study will evaluate the effectiveness of atomoxetine (Strattera) with and without Parent Management Training (PMT) in children with Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified…
- Conditions
- Autism, Pervasive Development Disorder, Asperger's Disorder, Attention Deficit Hyperactivity Disorder
- Trial name
- Strattera (NCT00844753)
- Testing
- atomoxetine, Parent Management Training
- Where
- 3 sites in United States
- Volunteers
- 128 people
- Sponsor
- University of Rochester